Related references
Note: Only part of the references are listed.In vivo targeting of B-cell lymphoma with glycan ligands of CD22
Weihsu C. Chen et al.
BLOOD (2010)
Siglecs as targets for therapy in immune-cell-mediated disease
Mary K. O'Reilly et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Sialoside analogue arrays for rapid identification of high affinity siglec ligands
Ola Blixt et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
J. F. DiJoseph et al.
LEUKEMIA (2007)
Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity
Hiroaki Tateno et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Siglecs and their roles in the immune system
Paul R. Crocker et al.
NATURE REVIEWS IMMUNOLOGY (2007)
High-affinity ligand probes of CD22 overcome the threshold set by cis ligands for binding, endocytosis, and killing of B cells
Brian E. Collins et al.
JOURNAL OF IMMUNOLOGY (2006)
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
RJ Kreitman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
